First-trimester placental protein 13 and placental growth factor: Markers for identification of women destined to develop early-onset pre-eclampsia

BJOG: An International Journal of Obstetrics and Gynaecology

Volumn 117, Issue 11, 2010, Pages 1384-1389

  Wortelboer, E J ^a   Koster, M P H ^b   Cuckle, H S ^c   Stoutenbeek, P ^a   Schielen, P C J I ^b   Visser, G H A ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^c Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

A desintegrin and metalloproteinase 12; first trimester; placental growth factor; placental protein 13; pre eclampsia

Indexed keywords

CHORIONIC GONADOTROPIN; DISINTEGRIN; MACROPHAGE ELASTASE; PLACENTA PROTEIN; PLACENTA PROTEIN 13; PLACENTAL GROWTH FACTOR; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CONTROLLED STUDY; CORRELATION COEFFICIENT; FEMALE; FIRST TRIMESTER PREGNANCY; HELLP SYNDROME; HEMOLYSIS; HUMAN; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PREECLAMPSIA; PRIORITY JOURNAL; TRISOMY 21;

ADAM PROTEINS; ADULT; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CHORIONIC GONADOTROPIN, BETA SUBUNIT, HUMAN; DISINTEGRINS; EARLY DIAGNOSIS; FEMALE; GALECTINS; HELLP SYNDROME; HUMANS; MEMBRANE PROTEINS; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY PROTEINS; PREGNANCY TRIMESTER, FIRST; PREGNANCY-ASSOCIATED PLASMA PROTEIN-A; PRENATAL DIAGNOSIS;

EID: 77956537077     PISSN: 14700328     EISSN: 14710528     Source Type: Journal    
DOI: 10.1111/j.1471-0528.2010.02690.x     Document Type: Article

References (19)

1. Laigaard J, Sorensen T, Placing S, Holck P, Frohlich C, Wojdemann KR, et al. Reduction of the disintegrin and metalloprotease ADAM12 in preeclampsia. Obstet Gynecol 2005 106: 144 149.
2. Spencer K, Cowans NJ, Stamatopoulou A. ADAM12s in maternal serum as a potential marker of pre-eclampsia. Prenat Diagn 2008 28: 212 216.
3. Romero R, Kusanovic JP, Than NG, Erez O, Gotsch F, Espinoza J, et al. First-trimester maternal serum PP13 in the risk assessment for preeclampsia. Am J Obstet Gynecol 2008 199: 122.
4. Levine RJ, Lam C, Qian C, Yu KF, Maynard SE, Sachs BP, et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 2006 355: 992 1005.
5. Torry DS, Wang HS, Wang TH, Caudle MR, Torry RJ. Preeclampsia is associated with reduced serum levels of placenta growth factor. Am J Obstet Gynecol 1998 179: 1539 1544.
6. Akolekar R, Zaragoza E, Poon LC, Pepes S, Nicolaides KH. Maternal serum placental growth factor at 11 + 0 to 13 + 6 weeks of gestation in the prediction of pre-eclampsia. Ultrasound Obstet Gynecol 2008 32: 732 739.
7. Brown MA, Lindheimer MD, de Swiet M, Van Assche A, Moutquin JM. The classification and diagnosis of the hypertensive disorders of pregnancy: statement from the International Society for the Study of Hypertension in Pregnancy (ISSHP). Hypertens Pregnancy 2001 20 (1 IX XIV.
8. Kloosterman GJ. On intrauterine growth; the significance of prenatal care. Int J Gynaecol Obstet 1970 8: 895 912.
9. Royston P, Thompson SG. Model-based screening by risk with application to Down's syndrome. Stat Med 1992 11: 257 268.
10. Cuckle HS, Arbuzova S. Multimarker maternal serum screening for chromosomal abnormalities. In: Milunski A, editor. Genetic Disorder and the Fetus: Diagnosis, Prevention, and Treatment. Baltimore: Johns Hopkins University Press 2004. pp. 795 835.
11. Cuckle HS, Wald NJ. Principles of screening. In: Wald N, Leck I, editors. Antenatal & Neonatal Screening, 2nd edn. Oxford: Oxford University Press 2000. pp. 3 22.
12. Wald NJ, Cuckle HS, Densem JW, Nanchahal K, Royston P, Chard T, et al. Maternal serum screening for Down's syndrome in early pregnancy. BMJ 1988 297 (6653 883 887.
13. Burger O, Pick E, Zwickel J, Klayman M, Meiri H, Slotky R, et al. Placental protein 13 (PP-13): effects on cultured trophoblasts, and its detection in human body fluids in normal and pathological pregnancies. Placenta 2004 25: 608 622.
14. Than NG, Pick E, Bellyei S, Szigeti A, Burger O, Berente Z, et al. Functional analyses of placental protein 13/galectin-13. Eur J Biochem 2004 271: 1065 1078.
15. Chafetz I, Kuhnreich I, Sammar M, Tal Y, Gibor Y, Meiri H, et al. First-trimester placental protein 13 screening for preeclampsia and intrauterine growth restriction. Am J Obstet Gynecol 2007 197: 35 7.
16. Livingston JC, Haddad B, Gorski LA, Neblett P, Ahokas RA, Ramsey R, et al. Placenta growth factor is not an early marker for the development of severe preeclampsia. Am J Obstet Gynecol 2001 184: 1218 1220.
17. Romero R, Nien JK, Espinoza J, Todem D, Fu W, Chung H, et al. A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate. J Matern Fetal Neonatal Med 2008 21: 9 23.
18. Erez O, Romero R, Espinoza J, Fu W, Todem D, Kusanovic JP, et al. The change in concentrations of angiogenic and anti-angiogenic factors in maternal plasma between the first and second trimesters in risk assessment for the subsequent development of preeclampsia and small-for-gestational age. J Matern Fetal Neonatal Med 2008 21: 279 287.
19. Poon LC, Chelemen T, Granvillano O, Pandeva I, Nicolaides KH. First-trimester maternal serum a disintegrin and metalloprotease 12 (ADAM12) and adverse pregnancy outcome. Obstet Gynecol 2008 112: 1082 1090.